NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / Technology News / Coronavirus vaccine in 2020? US drugmaker Pfizer isn't saying no!
    Coronavirus vaccine in 2020? US drugmaker Pfizer isn't saying no!
    1/8
    Technology 3 min read

    Coronavirus vaccine in 2020? US drugmaker Pfizer isn't saying no!

    By Shalini Ojha
    Oct 28, 2020
    07:40 pm
    Coronavirus vaccine in 2020? US drugmaker Pfizer isn't saying no!

    Even as experts worldwide have said that an effective coronavirus vaccine won't be out before 2021, American pharma giant Pfizer is hoping to deliver one this year itself, igniting hopes globally. The vaccine could be available in the US soon if clinical testing follows the expected timeline and regulators approve the doses, the company said on Tuesday. Here's more on this.

    2/8

    Company hoping to provide 40 million doses in US

    Pfizer's Chief Executive Albert Bourla said the company is looking at providing 40 million doses in the US this year. "If all goes well, we will be ready to distribute an initial number of doses," Bourla said, according to AFP. Pfizer's contract with the US government necessitates it to provide 40 million doses by this year and another 100 million doses by March 2021.

    3/8

    Expecting to file emergency use authorization before December: Bourla

    The top official said Pfizer is expecting to file for COVID-19 vaccine's emergency use authorization by the third week of November. When asked if he was being "bullish" about the vaccine's efficiency, Bourla said, "I'm not bullish a vaccine will work. I'm cautiously optimistic that the vaccine will work." Pfizer is working on the vaccine along with Germany's BioNTech SE.

    4/8

    Meanwhile, Pfizer said it still doesn't have late-stage trial data

    While the company is hoping to pull off the impossible, it also said that it still doesn't have data from the late-stage trials. Pfizer claimed that in the 44,000-volunteer trial, there hadn't been enough infections to understand whether the vaccine works or not, reports Reuters. A data monitoring board could make the first assessment after at least 32 participants contract the virus.

    5/8

    Data would definitely not be out before November 3 polls

    Bourla explained once the company has enough data, it would still take five-seven days before that information is made public. This means the findings will not be available before the November 3 elections. "For us, the election is an artificial milestone. This is going to be not a Republican vaccine or a Democrat vaccine. It will be a vaccine for the world," he said.

    6/8

    Pfizer expected to defeat rival Moderna in vaccine race

    Earlier, Pfizer had said data would be released this month, which would have made it the first US drugmaker to do so, before rival Moderna Inc. In fact, President Donald Trump also seemingly relied on Pfizer, which explains his confidence about a vaccine being available just in time for polls. US has already lost 232,084 to the contagious disease; Trump had also gotten infected.

    7/8

    Trial needs to consider high-risk people, opined expert

    On Pfizer's statement about trial data, Dr. David Boulware, professor of medicine at the University of Minnesota, said the study's participants could be more adherent to social distancing guidelines than the general population. "Who the vaccine trials really need are people who don't wear masks, who are going out to bars, who go to crowded events — those are the high-risk people," he said.

    8/8

    First generation of vaccine won't be perfect: UK taskforce

    With the globe pinning hopes on a vaccine, UK vaccine taskforce Chair Kate Bingham said on Tuesday that the first batch would not be that effective. "The first generation of vaccines is likely to be imperfect, and we should be prepared that they might not prevent infection but rather reduce symptoms, and, even then, might not work for everyone or for long," she said.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Donald Trump
    Pfizer
    United States of America
    Coronavirus
    Moderna Inc

    Donald Trump

    Days before US elections, Trump's pick confirmed to Supreme Court Supreme Court Of India
    US: Republican Nikki Haley declares China top national security threat Nikki Haley
    'Totally Under Control': Documentary exposes US's failure in tackling COVID-19 USA
    Biden slams Trump for his 'filthy' India remark during debate Kamala Harris

    Pfizer

    Johnson & Johnson's COVID-19 vaccine goes into final human trials Vaccine
    COVID-19 vaccine developers to pledge against rolling out shots prematurely Johnson & Johnson
    #VaccineTracker: Early COVID-19 vaccine results expected by September 15 United States of America
    Pfizer's COVID-19 vaccine shows promise in human trials: Details here Vaccine

    United States of America

    #ComicBytes: Five characters who replaced Steve Rogers as Captain America Civil War
    US stands with India against any threat, says Mike Pompeo India China Border
    OnePlus enters budget smartphone segment with Nord N100 and N10 Europe
    Threw us out: Ananya Birla calls out US restaurant Kumar Mangalam Birla

    Coronavirus

    Coronavirus: India's tally reaches 79.9 lakh; Delhi reports record spike India
    Coronavirus: Guidelines for 'reopening' from lockdown extended till November 30 India
    TN custodial deaths: CBI reveals how father, son were tortured Central Bureau Of Investigation (CBI)
    Coronavirus: India reports lowest single-day spike in over 3 months India

    Moderna Inc

    Big setback: Johnson & Johnson pauses coronavirus vaccine trial Johnson & Johnson
    Coronavirus: How much would the vaccines cost? Vaccine
    Moderna's COVID-19 vaccine goes into final human trial stage United States of America
    As coronavirus pandemic surges, some vaccine makers expect to profit Pfizer
    Next News Article

    Love Technology News?

    Subscribe to stay updated.

    Science Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023